Skip to main content

Cronobacter sakazakii: Are You Aligned With the FDA’s Recommendations?

In an effort to strengthen the infant formula supply chain's response to Cronobacter outbreaks, the FDA issued a call-to-action in March 2023 to enhance risk mitigation efforts.

Did you know that we offer a comprehensive suite of solutions and services that provides manufacturers with a complete set of augmented data that is in total alignment with the FDA’s call-to-action?

Fill out the short form below to download our infographic and learn how we can partner with you to check off each item on the call-to-action and further protect infant safety.

Additional Resources

CASE STUDY

Understanding & Mitigating Cronobacter Contamination: How An Infant Formula Manufacturer Saved $2 Million

An infant formula manufacturer recently confirmed C. sakazakii was present in the environment, raw materials, and in-process and finished product. When standard mitigation practices did not resolve the issues, they turned to bioMérieux to help solve their unanswered questions.

ACCESS CASE STUDY

OUR PORTFOLIO

Comprehensive Cronobacter Solutions

We help provide a complete set of augmented data that aligns with with the FDA’s recommendations, enabling more confident decisions from raw materials to finished products. Partner with bioMérieux to go beyond detection and fully understand the microbiome of your entire facility.

EXPLORE OUR OFFERING

CASE STUDY

Danone Nutricia Improves Pathogen Detection With bioMérieux Solutions

Nutricia needed a new PCR system that could handle an increased testing capacity for Salmonella, as well as a  second confirmation system for Cronobacter. bioMérieux provided a solution that led to an increase in analysis speed that helped increase production runs.

ACCESS CASE STUDY